Order Article Reprints

Cardenas FI, Mauguen A, Cheung IY, Kramer K, Kushner BH, Ragupathi G, Cheung N-KV, Modak S. Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers. 2021; 13(24):6265. https://doi.org/10.3390/cancers13246265

Cardenas, Fiorella Iglesias, Audrey Mauguen, Irene Y. Cheung, Kim Kramer, Brian H. Kushner, Govind Ragupathi, Nai-Kong V. Cheung, and Shakeel Modak. 2021. "Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma" Cancers 13, no. 24: 6265. https://doi.org/10.3390/cancers13246265

Cardenas, F. I., Mauguen, A., Cheung, I. Y., Kramer, K., Kushner, B. H., Ragupathi, G., Cheung, N. -K. V., & Modak, S. (2021). Phase I Trial of Oral Yeast-Derived β-Glucan to Enhance Anti-GD2 Immunotherapy of Resistant High-Risk Neuroblastoma. Cancers, 13(24), 6265. https://doi.org/10.3390/cancers13246265